Nature Biotechnology Announces Publication of Paper Describing Creation of Insulin-Producing Cells from Human Embryonic Stem Cells by Novocell’s K.A. D’Amour, et al.
The following is excerpted from a press release, dated October 19, 2006, from the journal Nature Biotechnology, which references the paper Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells by K.A. D’Amour, et al.
Insulin-Producing Cells From Human Embryonic Stem Cells
The culture conditions under which human embryonic stem cells can be converted into cells that produce all five hormones made by the pancreas, including insulin, are reported online in Nature Biotechnology this week. Baetge and colleagues’ study suggests that the possibility of turning human embryonic stem cells into pancreatic cells that can be used for diabetes therapy has moved one step closer to reality.
Human embryonic stem cells have the potential to become virtually any cell type in the body. Thus, they are a promising source of cells to repair damaged organs like the pancreas, heart and liver. The challenge facing scientists is to unlock the secrets of how to produce particular cell types, such as pancreatic beta-cells – the insulin-secreting cells in the pancreas – with high efficiency.
Baetge and colleagues show that the efficient generation of insulin-producing cells from human embryonic stem cells depends on guiding the cells through stages similar to those of pancreatic development, including the critical early developmental stage known as ‘definitive endoderm.’ The insulin-producing cells the authors created contained high levels of insulin. They were also capable of secreting insulin, but only minimally in response to sugar – a crucial function of adult beta-cells. Thus, the cells seem closer to immature, fetal beta-cells. The authors speculate that with additional research these cells could be matured into insulin-producing cells that are suitable for transplantation into patients.
About Nature Publishing Group
Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG’s flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through email@example.com and scientific career information through Naturejobs.
NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to www.nature.com.
About Novocell, Inc.
Novocell, Inc. is a stem cell engineering company with research operations in Irvine and San Diego, CA, and Athens, GA, dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell has three primary technologies: stem cell-directed lineage, encapsulation and drug discovery. The company was founded in 1999 and merged with CyThera and BresaGen in 2004.